查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425121

胚胎着床前基因检测市场－2024年至2029年预测

Preimplantation Genetic Testing Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 141 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计胚胎着床前基因检测市场在预测期内将以 10.26% 的复合年增长率成长。

胚胎着床前遗传学诊断 (PGD) 在 IVF 之前进行。对于多次流产且上次妊娠出现染色体异常的女性，PGD 被引入 IVF 週期。有遗传性疾病风险的夫妇可以从胚胎着床前基因检测中受益。

胚胎着床前基因检测市场的驱动因素

影响胚胎着床前基因治疗产业成长的主要因素是不孕症发生频率的增加和个体遗传问题数量的增加。胚胎着床前基因检测的需求量很大，因为它可以检测有缺陷的胚胎以及多种遗传性疾病和其他导致儿童出生时有健康缺陷的缺陷。单一基因捐赠者、患有性别相关遗传疾病、染色体问题或多次流产的个体越来越多地利用胚胎着床前基因检测方法。

新生儿死亡人数增加

许多遗传畸形是导致全球新生儿死亡的原因，推动了胚胎着床前基因治疗市场的成长。例如，根据联合国儿童基金会的数据，2021 年每天将有 6,400 名新生儿死亡。此外，全球每 1,000 名活产婴儿中有 18 人死亡，这使得出生后第一个月对新生儿来说是最危险的。胚胎着床前遗传学诊断可以透过早期检测染色体缺陷并预防胎儿先天性遗传畸形来帮助遏制这一问题。随着女性生育年龄的增加，胚胎着床前基因检测的使用也增加。

增加聚合酵素链锁反应的采用

在预测期内，聚合酵素链锁反应将占据最大的市场占有率，因为成本效益的上升以及PCR测试的高市场渗透率和高精度正在推动其在胚胎着床前基因治疗行业的份额。聚合酵素链锁反应增加了检测具有高拷贝数的特定基因拉伸的染色体异常的可能性。该技术适用于所有类型的基因诊断。

胚胎着床前遗传学诊断的普及

推动胚胎着床前基因治疗市场成长的主要因素是医疗保健专业人员和消费者对基因检测的认识不断提高。越来越多的单基因疾病和易位病例使得NGS技术在基因检测方面变得有效。胚胎着床前遗传学诊断（PGD）服务有助于降低遗传疾病的发生率，这是透过胚胎测试来确定特定的基因突变来完成的。 PGS 服务也越来越受欢迎，因为提案接受多个 IVF 週期、高龄和反覆流产的夫妇使用。

医疗科技的进步

对改善卫生服务的需求不断增长和收入的增加正在推动先进诊断和治疗方法的发展。随着预防身体异常和健康问题的需求增加，胚胎着床前基因治疗市场见证了早期诊断方法的成长。这些早期诊断方法用于遗传体外受精和其他形式的人工授精。胚胎着床前基因检测方法可以检测先天性听力损失和囊肿纤维化等遗传性疾病。

采用新一代定序技术

次世代定序仪以其高精度、高效和全面的遗传讯息正在推动胚胎着床前基因治疗产业的发展。次世代定序方法提供详细的遗传分析，可以提高辅助生殖技术的成功率。此外，由于胚胎着床前胚胎中染色体异常的需求不断增加，萤光原位杂合技术的采用也对胚胎着床前基因治疗市场产生了重大影响。 FISH 提供快速结果并一次筛检有限数量的染色体。

IVF预后预测可望占据较大市场占有率

胚胎着床前基因检测在IVF预后诊断中发挥重要作用，因为它需要检测胚胎的医学状况，并有助于IVF预后诊断的成长。由于体外受精的高需求，对胚胎着床前基因检测的需求不断增加。此外，主要市场参与者推出的众多产品进一步推动了胚胎着床前基因治疗市场的成长。不孕症发生率的上升和对体外受精的日益偏好预计将在预测期内推动胚胎着床前基因治疗市场的成长。

在欧洲，胚胎着床前基因检测市场预计将稳定成长。

预计欧洲地区将在胚胎着床前基因治疗市场占据主要份额。该地区的胚胎着床前基因治疗市场将因妊娠晚期盛行率的上升而受到推动。此外，欧洲国家日益宽鬆的筛检法规以及强大市场参与者的存在正在推动该地区的胚胎着床前基因治疗产业的发展。此外，由于生殖医学的进步，预计亚太地区在预测期内将大幅成长。体外受精的高普及率和消费者意识的提高进一步推动了胚胎着床前基因治疗市场的成长。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章胚胎着床前基因检测市场：依技术分类

  • 介绍
  • 次世代定序
  • 聚合酵素链锁反应
  • 萤光原位杂合反应
  • 比较杂合反应
  • 单分子多态性

第六章胚胎着床前基因检测市场：依程序类型

  • 介绍
  • 胚胎着床前基因筛检
  • 胚胎着床前遗传学诊断

第七章胚胎着床前基因检测市场：依应用分类

  • 介绍
  • 非整倍体
  • 单基因疾病
  • X连锁疾病
  • 其他的

第八章胚胎着床前基因检测市场：依最终用户分类

  • 介绍
  • 产科诊所
  • 医院
  • 其他的

第九章胚胎着床前基因检测市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十一章 公司简介

  • Milann Fertility Center
  • Pac Genomics
  • Thermo Fisher Scientific
  • Natera
  • Illumina
  • Johns Hopkins Medicine
  • NYU Langone Health
  • Cloudnine Fertility
  • MedGenome
  • CNY Fertility
简介目录
Product Code: KSI061616223

The preimplantation genetic testing market is estimated to grow at a CAGR of 10.26% during the forecast period.

Preimplantation genetic diagnosis (PGD) is implemented before IVF workflow. For women who have had several miscarriages and last pregnancy with chromosome abnormality have PGD deployed in IVF cycles. Couples who are at risk of hereditary disorders can benefit from preimplantation genetic testing.

Driving factors for the preimplantation genetic testing market

The major factor influencing the growth of the preimplantation genetic treatment industry is the growing frequency of infertility among individuals and rising genetic problems. Preimplantation genetic testing is growing in demand as it detects defective embryos and has some genetic disorders and other faults that lead to the child being born with health defects. Individuals who have single gene donors, sex-linked genetic disorders, chromosomal problems, or have a history of multiple abortions are increasingly using preimplantation genetic testing methods.

Growing prevalence of neo-natal deaths

Many genetic deformities cause newborn deaths around the globe and hence will propel the growth of the preimplantation genetic treatment market. For instance, according to UNICEF, 6,400 newborns died every day in 2021. Furthermore, there were 18 deaths per thousand live births worldwide making the first month the most dangerous for newborns. Preimplantation genetic diagnosis helps in curbing this issue as it detects defective chromosomes at an early stage and prevents congenital genetic deformities in the fetuses. As the women's age for childbearing increases so is the use of preimplantation genetic testing.

Rising adoption of polymerase chain reaction

Polymerase chain reaction is anticipated to hold the maximum market share during the forecast period owing to the high market penetration and rising cost-effectiveness with high accuracy of PCR tests are fueling the preimplantation genetic treatment industry share. The polymerase chain reaction increases the chance of detection of any chromosomal abnormalities with a large number of copies of a particular stretch of the genome. This technology is suitable for all types of genetic diagnosis.

Growing prevalence of preimplantation genetic diagnosis

The major factor driving the growth of the preimplantation genetic treatment market is the growing awareness among healthcare professionals and consumers about genetic testing. The rising incidence of single gene disease and translocation cases led to the effective delivery of NGS technology for genetic testing. The preimplantation genetic diagnosis (PGD) services help reduce the incidences of genetic diseases which is done by embryo examination to determine specific gene mutations. The PGS services are also gaining popularity as they are suggested for couples with multiple IVF cycles, advanced age, and recurrent pregnancy loss.

Advancements in medical technologies

The growing demand for improved medical services and increasing income is fueling opportunities for the development of advanced diagnostic and treatment approaches. As the need to prevent physical abnormalities and health problems has increased the preimplantation genetic treatment market has seen growth for early diagnostic approaches. These early diagnostic approaches are being used during genetic invitro fertilization and other artificial insemination procedures. Preimplantation genetic testing methods can detect inherited disorders including congenital hearing loss, cystic fibrosis, and many more.

Adoption of next-generation sequencing technology

Next-generation sequencing drives the preimplantation genetic treatment industry due to its high accuracy, efficiency, and comprehensive genetic information. The next-generation sequencing method provides detailed genetic analysis which results in improved success rates of assisted reproductive techniques. Moreover, the adoption of florescent in-situ hybridization is also significantly impacting the preimplantation genetic treatment market due to the growing need to detect chromosomal abnormalities in embryos before implantation. FISH offers rapid results and screens a limited number of chromosomes at a time.

IVF Prognosis is anticipated to hold a significant market share

Preimplantation genetic testing plays an important role in IVF prognosis as it is necessary to inspect the medical condition of the embryos, thereby contributing to the growth of IVF prognosis. The high demand for invitro fertilization procedures is increasing the demand for preimplantation genetic testing procedures in the market. Additionally, many product launches by major market players are further fueling the preimplantation genetic treatment market growth. Rising infertility and increasing preference for IVF procedures are expected to drive the growth of the preimplantation genetic treatment market during the forecast period.

In Europe, it is projected that the preimplantation genetic testing market will grow steadily.

The European region is anticipated to secure a sizable preimplantation genetic treatment market share. The regional preimplantation genetic treatment market will be fueled by the increasing prevalence of late pregnancies. Additionally, the growing liberal regulations in various countries in Europe for screening and the presence of leading market players are fueling the regional preimplantation genetic treatment industry. Furthermore, Asia Pacific is anticipated to grow significantly during the forecast period due to advancements in reproductive health. High adoption of IVF and increasing consumer awareness are further fueling the preimplantation genetic treatment market growth.

Market Key Developments

  • In April 2023, The HelpCureHD Foundation and Prelude Network launched the More Than Fertility campaign to increase and educate awareness about IVF with Preimplantation Genetic Testing.
  • In October 2022, Genomic Prediction and HelpCureHD collaborated to help partners with the risk of Huntington's disease screen through preimplantation genetic testing.
  • In October 2022, Ovation Fertility and Genomic Prediction partners to license the LifeView PGT platform.
  • In July 2022, To screen genetic diseases in IVF embryos, GenEmbryomics launched research using genome sequencing tests.

Segmentation:

By Technology

  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Fluorescent In-Situ Hybridization
  • Comparative Genomic Hybridization
  • Single Molecule Polymorphism

By Procedure Type

  • Preimplantation Genetic Screening
  • Preimplantation Genetic Diagnosis

By Application

  • Aneuploidy
  • Single Gene Disorders
  • X-linked Disorders
  • Others

By End-User

  • Maternity Clinics
  • Hospitals
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Next Generation Sequencing
  • 5.3. Polymerase Chain Reaction
  • 5.4. Fluorescent In-Situ Hybridization
  • 5.5. Comparative Genomic Hybridization
  • 5.6. Single Molecule Polymorphism

6. PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE

  • 6.1. Introduction
  • 6.2. Preimplantation Genetic Screening
  • 6.3. Preimplantation Genetic Diagnosis

7. PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Aneuploidy
  • 7.3. Single Gene Disorders
  • 7.4. X-linked Disorders
  • 7.5. Others

8. PREIMPLANTATION GENETIC TESTING MARKET, BY END-USER

  • 8.1. Introduction
  • 8.2. Maternity Clinics
  • 8.3. Hospitals
  • 8.4. Others

9. PREIMPLANTATION GENETIC TESTING MARKET, BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. The Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. Japan
    • 9.6.2. China
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

  • 11.1. Milann Fertility Center
  • 11.2. Pac Genomics
  • 11.3. Thermo Fisher Scientific
  • 11.4. Natera
  • 11.5. Illumina
  • 11.6. Johns Hopkins Medicine
  • 11.7. NYU Langone Health
  • 11.8. Cloudnine Fertility
  • 11.9. MedGenome
  • 11.10. CNY Fertility